TrialAnnals of the rheumatic diseases2011
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
Gerd R Burmester et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
67 papers cite itlatest 60 shown
this paperpooled ittrialcites it